Business Wire

Inaugural Dealroom and NATO Innovation Fund Report Reveals Record-Breaking Investing in Startups in European Defence, Security, and Resilience Sector

Share

The Defence, Security and Resilience sector reached $5.2 billion in 2024, an all-time high.The sector has outperformed the overall VC (Venture Capital) sector, marking a 30 percent increase over the past two years.Munich has emerged as the top VC hub in Europe for this segment in 2024.To help support the integration of the growing number of emerging technologies in this segment by governments and businesses, the NATO Innovation Fund is announcing the hiring of John Ridge as Chief Adoption Officer.

Dealroom.co and the NATO Innovation Fund - a €1 billion VC (Venture Capital) backed by 24 NATO countries – published today their inaugural report on the state of Defence, Security and Resilience in Europe, revealing a record-breaking year for investing in this segment. This highlights the critical role that the sector is playing in maintaining Europe’s technological edge and sovereignty amidst a broader market downturn.

Key findings from the report reveal:

  1. VC funding in the DSR (defence, security and resilience) sector is at an all-time high, reaching $5.2 billion in 2024. Overall, investing is up nearly 5x in the last six years. With companies in early and breakout stages driving this growth, a strong pipeline to scaling is expected in the coming years.
  2. DSR investing has increased by 30 percent over the past two years - the strongest growth among all VC deep tech segments. The segment has significantly outperformed the overall VC market, which witnessed a 45 percent decline in the same period of time.
  3. Defence startups have been leading in the segment’s growth. Companies developing technologies for Awareness, Understanding, and Decision Making – this includes technologies that help track risks and threats to enable faster and better decisions - have seen VC funding soar to a record $1 billion in 2024, up 4x since 2020 and nearly 2x since last year.

“Appetite for defence, security and resilience startup investment is unrecognisable in Europe from just a few years ago,” said Yoram Wijngaarde, Founder and CEO of Dealroom. “While overall VC funding contracted by 45 percent in the past two years, defence and security tech investment has grown by 30 percent to reach $5.2 billion last year. It follows an ongoing trend of putting capital and innovation to work on Europe's core strategic needs, via deep technologies. Despite recent growth, defence, security and resilience tech remains a relatively nascent sector, but the data shows an active pipeline of early-stage companies looking to change that.”

“Europe has the talent and resources to become a global leader in technologies for Defence, Security and Resilience,” said Kelly Chen, Partner at the NATO Innovation Fund. “We're excited to see this sector drive the momentum in Deep Tech this year and are committed to investing in technologies that can secure the region's future.”

Germany and the UK are emerging as regional leaders

  1. Munich emerged as Europe's top hub for DSR investment, followed by Oxford in the UK and Paris in France.
  2. The UK has attracted the most VC funding in DSR since 2019. However, Germany claimed the top spot in 2024, followed by the UK and France.
  3. Since 2019, Switzerland and the Netherlands have invested 7 percent of their total national VC funding in DSR companies. That marks the largest share of national funding invested in this segment.
  4. The UK boasts five of the top ten DSR hubs (Oxford, London, Cambridge, Bristol, and Reading), while Germany follows with two (Munich, Berlin).

“The Munich metropolitan region is becoming a hub for next-generation defence companies, offering industrial and testing facilities, top talent, a regional industrial supply chain, and connections to German defence customers and traditional primes,” said Marc Wietfeld, Co-Founder & CEO, ARX. “With ARX, we aim to bridge the gap between emerging players, new defence primes, and established contractors.”

Laying the foundation for technological adoption in Europe

The report’s findings indicate that Europe's emerging tech landscape is undergoing a significant transformation in the defence, security and resilience space, driven by geopolitical developments and a growing demand for emerging technologies that can secure the region’s future. In a recently released paper, the NATO Innovation Fund called for the creation of adoption pathways for the integration of emerging technologies in the defence and security infrastructure of European ministries of defence.

To help support with the creation of these pathways, as well as in order to connect large European businesses with startup founders who have developed deep tech solutions that can help the region maintain its technological edge for generations to come, the NATO Innovation Fund is announcing today the hiring of John Ridge as Chief Adoption Officer.

John joins the NATO Innovation Fund after spending nearly three decades in the UK’s Armed Forces and Civil Service. He is also a Commissioner on the Atlantic Council’s current Commission on Software-Defined Warfare.

“I am extremely proud to be joining the NATO Innovation Fund to help get the cutting-edge capabilities of our portfolio companies into the hands of users across the Alliance,” said John Ridge, Chief Adoption Officer, NATO Innovation Fund. “I look forward to working hand-in-hand with NATO, national governments and defence industry leaders to help the technologies that we are backing make a difference to the Alliance's ability to deter further aggression by our adversaries.”

About the NATO Innovation Fund:

The NATO Innovation Fund is a €1 billion venture capital fund, backed by 24 NATO Allies, that invests in deep tech to address challenges in defence, security, and resilience. The fund invests independently, with 24 nations supporting its portfolio’s success and helping provide deep tech entrepreneurs with access to both commercial and government markets.

Participating NATO Allies are: Belgium; Bulgaria; Czechia; Denmark; Estonia; Finland; Germany; Greece; Hungary; Iceland; Italy; Latvia; Lithuania; Luxembourg; Netherlands; Norway; Poland; Portugal; Romania; Slovakia; Spain; Sweden; Türkiye; United Kingdom.

About Dealroom.co:

Dealroom.co is a global intelligence platform for discovering and tracking the most promising companies, technologies and ecosystems. Clients include many of the world’s foremost organizations such as Sequoia, Accel, Index Ventures, NATO Innovation Fund, Nato Diana, ESA, McKinsey, BCG, Deloitte, Google, AWS, Microsoft, Stripe.

Dealroom partners closely with local tech ecosystem development agencies and enablers, to create a comprehensive multi-dimensional blueprint of the tech ecosystem, including capital, talent, innovation, entrepreneurship and overall economic dynamism.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250211886043/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye